Evidence map›Paper›PMID 31240402›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2019

α-Synuclein in Parkinson's disease: causal or bystander?

Peter Riederer, Daniela Berg, Nicolas Casadei, Fubo Cheng, Joseph Classen, Christian Dresel, Wolfgang Jost, Rejko Krüger, Thomas Müller, Heinz Reichmann and 10 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 112 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. The brain and heart-axis in neurodegeneration and cardiovascular disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  8. Review
  9. Review
  10. Movement disorders: a brief overview from an evolutionary perspective.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  11. Review
  12. Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  13. Review
  14. Review
  15. Clinicians' viewpoints on current paradigms of care and research in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  16. Therapy with botulinum neurotoxin for Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 14 institutions in 2 countries.

Peter RiedererClinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, University of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany. peter.riederer@mail.uni-wuerzburg.de.
Daniela BergDepartment of Neurology, UKHS, Christian-Albrechts-Universität, Campus Kiel, Kiel, Germany.
Nicolas CasadeiNGS Competence Center Tübingen, Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Fubo ChengNGS Competence Center Tübingen, Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Joseph ClassenDepartment of Neurology, University Hospital Leipzig, Leipzig, Germany.
Christian DreselDepartment of Neurology, Center for Movement Disorders, Neuroimaging Center Mainz, Clinical Neurophysiology, Forschungszentrum Translationale Neurowissenschaften (FTN), Rhein-Main-Neuronetz, Mainz, Germany.
Wolfgang JostParkinson-Klinik Ortenau, Wolfach, Germany.
Rejko KrügerClinical and Experimental Neuroscience, LCSB (Luxembourg Centre for Systems, Biomedicine), University of Luxembourg, Esch-sur-Alzette and Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg.
Thomas MüllerDepartment of Neurology, Alexianer St. Joseph Berlin-Weißensee, Berlin, Germany.
Heinz ReichmannDepartment of Neurology, University of Dresden, Dresden, Germany.
Olaf RießInstitute of Medical Genetics and Applied Genomics, Tübingen, Germany.
Alexander StorchDepartment of Neurology, University of Rostock, Rostock, Germany.
Sabrina StrobelDepartment of Neuropathology, Institute of Pathology, University of Würzburg, Würzburg, Germany.
Thilo van EimerenDepartment of Neurology, University Hospital of Cologne, Cologne, Germany.
Hans-Ullrich VölkerDepartment of Pathology, Leopoldina Hospital, Schweinfurt, Germany.
Jürgen WinklerDepartment Kopfkliniken, Molekulare Neurologie, Universitätsklinikum Erlangen, Erlangen, Germany.
Konstanze F WinklhoferInstitute of Biochemistry and Pathobiochemistry, Ruhr-Universität Bochum, Bochum, Germany.
Ullrich WüllnerDepartment of Neurology, University of Bonn, German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany.
Friederike ZunkeDepartment of Biochemistry, Medical Faculty, University of Kiel, Kiel, Germany.
Camelia-Maria MonoranuDepartment of Neuropathology, Institute of Pathology, University of Würzburg, Würzburg, Germany.
University of Tübingen · DEUniversity of Würzburg · DEKiel University · DECentre Hospitalier de Luxembourg · LUGerman Center for Neurodegenerative Diseases · DELeopoldina Krankenhaus Schweinfurt · DEParkinson-Klinik Ortenau · DERuhr University Bochum · DESt. Joseph-Krankenhaus · DETU Dresden · DEUniversitätsklinikum Erlangen · DEUniversity Hospital Cologne · DEUniversity Hospital Leipzig · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) comprises a spectrum of disorders with differing subtypes, the vast majority of which share Lewy bodies (LB) as a characteristic pathological hallmark. The process(es) underlying LB generation and its causal trigger molecules are not yet fully understood. α-Synuclein (α-syn) is a major component of LB and SNCA gene missense mutations or duplications/triplications are causal for rare hereditary forms of PD. As typical sporadic PD is associated with LB pathology, a factor of major importance is the study of the α-syn protein and its pathology. α-Syn pathology is, however, also evident in multiple system atrophy (MSA) and Lewy body disease (LBD), making it non-specific for PD. In addition, there is an overlap of these α-synucleinopathies with other protein-misfolding diseases. It has been proven that α-syn, phosphorylated tau protein (pτ), amyloid beta (Aβ) and other proteins show synergistic effects in the underlying pathogenic mechanisms. Multiple cell death mechanisms can induce pathological protein-cascades, but this can also be a reverse process. This holds true for the early phases of the disease process and especially for the progression of PD. In conclusion, while rare SNCA gene mutations are causal for a minority of familial PD patients, in sporadic PD (where common SNCA polymorphisms are the most consistent genetic risk factor across populations worldwide, accounting for 95% of PD patients) α-syn pathology is an important feature. Conversely, with regard to the etiopathogenesis of α-synucleinopathies PD, MSA and LBD, α-syn is rather a bystander contributing to multiple neurodegenerative processes, which overlap in their composition and individual strength. Therapeutic developments aiming to impact on α-syn pathology should take this fact into consideration.

Indexed as

alpha-SynucleinAnimalsHumansParkinson Diseasealpha-SynucleinAutophagyGene expressionLysosomeNeuroinflammationNeuromelaninParkinson’s diseaseProteasomeProtein interactionsSNCA geneSynucleinopathyTherapyα-Synuclein

Identifiers

PMID31240402
OpenAlexW2954935089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.